COVlD-19 vaccine Distribution: Preparing for the Unexpected
Pharmaceutical Technology Europe
; 33(1):25-26, 2021.
Article
Dans Anglais
| ProQuest Central | ID: covidwho-20242753
ABSTRACT
In December 2020, two shipments of the vaccine experienced temperature excursions in which product was actually kept at overly cold temperatures (3). Urgent need to protect data One problem that vaccine developers and regulatory agencies need to address is the urgent need to protect data, says Nigel Thorpe, technology director with Secure Age, which specializes in enterprise data encryption using a public key infrastructure platform. For operators on the plant floor, the efforts required are fraught with potential error, especially during shift changes, says Jim Evans, director of Verista, Inc.'s vision, connectivity, and automation division. Raw materials The speed with which vaccines have been developed and are being distributed pose important questions centred around variability. If we're having a raw materials shortage when the vaccines haven't even been scaled up, what will happen when they get full approval?" he asks.
Pharmacy And Pharmacology; Innovations; Raw materials; Data integrity; COVID-19 vaccines; mRNA vaccines; FDA approval; Temperature; Public Key Infrastructure; Pharmaceutical industry; Supply chains; Shipments; Data encryption; Manufacturing; Research & development--R&D; Drug dosages; United States--US; 32541:Pharmaceutical and Medicine Manufacturing
Collection:
Bases de données des oragnisations internationales
Base de données:
ProQuest Central
Les sujets:
Vaccins
langue:
Anglais
Revue:
Pharmaceutical Technology Europe
Année:
2021
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS